– USA, MA – resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced the appointment of Jeffrey Chodakewitz, M.D., to its Board of Directors.
“Jeffrey’s extensive experience with clinical and pipeline development, including the fields of respiratory and infectious diseases, makes him a highly valuable addition to our Board of Directors,” said Chen Schor, President and CEO of resTORbio. “We are delighted to welcome Jeffrey and look forward to his contributions as we progress RTB101 into pivotal trials to reduce the incidence of respiratory tract infections and initiate additional studies to examine the benefits of TORC1 inhibition in other aging-related diseases.”
Dr. Chodakewitz has decades of experience holding leadership positions in world class drug development organizations. He currently serves as Executive Vice President, Clinical Medicine and External Innovation, at Vertex Pharmaceuticals. Until April 2018, Dr. Chodakewitz held the roles of Chief Medical Officer and Executive Vice President, Global Medicines Development and Medical Affairs, at Vertex and was a member of the Vertex Executive Committee. Prior to joining Vertex in 2014, he spent over 20 years at Merck & Co., where he served in a number of positions including Head of Infectious Diseases and Vaccines Global Development, Senior Vice President of Global Scientific Strategy (Infectious Disease, Respiratory & Immunology) and Senior Vice President of Late Stage Development. Prior to Merck, he served in academic positions at Yale University School of Medicine and New York University’s Bellevue Medical Center. Dr. Chodakewitz is a Diplomate of the National Board of Medical Examiners and the American Board of Internal Medicine (both Internal Medicine and Infectious Disease). He holds a B.S in Biochemistry cum laude from Yale University and an M.D. from the Yale University School of Medicine.
“I am thrilled to join resTORbio’s Board as the Company progresses RTB101 into late-stage clinical development and gains additional insights on the potential benefits of TORC1 inhibition in other indications,” said Dr. Chodakewitz. “I look forward to working with the team to further advance our leadership in TORC1 inhibition and the treatment of aging-related diseases.”
resTORbio, Inc. is a clinical stage biopharmaceutical company targeting TORC1 and other biological pathways that regulate aging to develop innovative medicines with the potential to extend healthy lifespan. resTORbio’s lead program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiovascular and central nervous systems.
For more information : https://www.restorbio.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.